Sichuan Hebang Biotechnology (603077.SH) issued a profit warning, expecting a 96.88% to 97.66% year-on-year decline in net profit for the fiscal year 2024.
Habio (603077.SH) announces a decrease in performance forecast for the year 2024, expecting a decrease in net profit...
Sichuan Hebang Biotechnology (603077.SH) announced a forecasted decrease in performance for the year 2024, estimating a net profit attributable to shareholders of the listed company of 30 to 40 million yuan, a year-on-year decrease of 96.88% to 97.66%.
Related Articles
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.
Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
